Acromegaly: Pathophysiology and Etiology

Welcome to your first lesson on acromegaly. As we established, this course will provide a focused review of the core aspects of this condition. We will begin by building a solid theoretical foundation, starting with the fundamental "how" and "why" of the disease.

This lesson addresses the first learning outcome: explaining the pathophysiology of acromegaly by linking growth hormone (GH) excess to elevated insulin-like growth factor 1 (IGF-1), and identifying the primary causes (etiologies) of the condition. By the end of this session, you will have a clear understanding of the hormonal cascade that goes awry and the types of pathologies that initiate this process.

The GH-IGF-1 Axis: A Tale of a Hormone and its Mediator

From your background in endocrinology, you are familiar with the concept of hypothalamic-pituitary axes. The growth hormone axis follows this classic model, with a crucial addition: a mediator that carries out many of its downstream effects.

Growth hormone (GH) is secreted by somatotroph cells in the anterior pituitary, regulated by two hypothalamic hormones:

Growth Hormone-Releasing Hormone (GHRH): Stimulates GH release.
Somatostatin: Inhibits GH release.

However, GH does not act alone. A significant portion of its growth-promoting and metabolic actions are mediated by Insulin-like Growth Factor 1 (IGF-1), which is produced primarily in the liver under the stimulation of GH. IGF-1 is the key effector hormone that acts on target tissues throughout the body.

The following video provides an excellent explanation of IGF-1's role as the "middleman" for growth hormone. It highlights a critical concept: the difference in their biological half-lives.

Insulin-like growth factor (IGF-1) - Somatomedin C - GH- Dwarfism, Gigantism, Acromegaly - Endocrine

Please watch the video "Insulin-like growth factor (IGF-1)" from the Medicosis Perfectionalis channel. It vividly explains the relationship between GH and IGF-1.

Focus on two key segments. First, watch the explanation of the middleman concept, where the narrator explains why GH needs IGF-1 to mediate its effects on tissues like cartilage. Then, pay attention to the discussion on half-life and function, which compares the very short half-life of GH to the much longer half-life of IGF-1. This distinction is crucial for both pathophysiology and diagnosis.

As the video explains, GH has a half-life of less than 20 minutes and is released in a pulsatile fashion. In contrast, IGF-1 has a half-life of about 20 hours, providing a more stable and integrated measure of daily GH secretion. This is why IGF-1, not GH itself, is the primary screening tool for acromegaly, a topic we will delve into in a future lesson.

The Pathophysiology of Acromegaly: A Broken Feedback Loop

Acromegaly is fundamentally a disorder of chronic, unregulated GH hypersecretion. This autonomous GH production leads to a persistent elevation of IGF-1, which drives the majority of the clinical and metabolic manifestations of the disease.

In a healthy individual, high levels of IGF-1 would trigger a negative feedback loop, suppressing GH secretion from the pituitary and GHRH from the hypothalamus. In acromegaly, this feedback mechanism is broken because the source of GH (most often a pituitary adenoma) is no longer responsive to normal physiological control.

The diagram below contrasts the physiological state with the pathological state of acromegaly, highlighting the impaired feedback and the resulting systemic effects.

This diagram illustrates the consequences of GH excess in acromegaly. Note the impaired negative feedback loop, leading to persistently high GH and IGF-1 levels. This results in pathological changes in the pancreas, adipose tissue, muscle, and liver, contributing to the metabolic dysfunction characteristic of the disease.

The constant stimulation by high GH and IGF-1 levels leads to:

Somatic Overgrowth: Proliferation of bone, cartilage, and soft tissues, leading to the physical features we will discuss in the next lesson.
Metabolic Dysfunction: As shown in the diagram, GH has anti-insulin effects. Its excess leads to increased lipolysis, increased hepatic gluconeogenesis, and reduced peripheral glucose uptake, all contributing to insulin resistance and a high prevalence of diabetes mellitus.

The Etiology of Acromegaly: Where Does the Excess GH Come From?

Now that we understand the hormonal dysregulation, the next logical question is: what causes it? The origins of acromegaly can be divided into two main categories, but one is far more common than the other.

The diagram below provides a clear visual summary of the primary etiologies.

This flowchart details the causes of acromegaly. On the left, it shows that over 99% of cases are due to central GH excess, primarily from a pituitary adenoma. On the right, it illustrates the rare causes (<1%) of ectopic GHRH or GH secretion from various tumors.

As the diagram makes clear, the overwhelming majority of cases stem from a primary pituitary pathology.

1. Central GH Excess (>99% of cases)

This category refers to problems originating within the pituitary gland itself.

GH-Secreting Pituitary Adenoma: This is the cause in more than 99% of patients. These are benign monoclonal tumors of the somatotroph cells that secrete GH autonomously. Most are sporadic, though they can be associated with certain genetic syndromes (e.g., MEN1, McCune-Albright syndrome) as listed in the diagram.
Pituitary Carcinoma: An extremely rare malignant variant.
Primary Hyperplasia: Diffuse or nodular enlargement and overactivity of somatotroph cells, which is also very rare.

2. Ectopic Hormone Production (<1% of cases)

In very rare instances, the problem lies outside the pituitary. This can happen in two ways:

Ectopic GHRH Secretion: A non-pituitary tumor produces GHRH, which chronically overstimulates the otherwise normal somatotroph cells in the pituitary to the point of hyperplasia and hypersecretion of GH. These are typically neuroendocrine tumors, such as those in the lung (bronchial carcinoid) or pancreas.
Ectopic GH Secretion: This is the rarest cause, where a non-pituitary tumor (e.g., pancreatic tumor, lymphoma) produces GH itself. In this scenario, the pituitary gland is often suppressed.

To consolidate your understanding of these causes, please review the "Etiology" section in the StatPearls article on acromegaly. It provides a concise and well-organized list that complements the diagram above.

Acromegaly - StatPearls - NCBI Bookshelf - NIH

This section provides a clear, categorized summary of the causes of acromegaly.

Read the entire Etiology section. Pay attention to how it classifies the causes into primary GH excess, ectopic GH excess, and GHRH excess, and note the examples given for each.

Conclusion

In this lesson, we have established the foundational pathophysiology and etiology of acromegaly.

Key Takeaways:

Acromegaly is a syndrome of chronic GH excess, which leads to sustained elevation of its mediator, IGF-1.
The disease results from a failure of the normal negative feedback mechanisms that control the GH-IGF-1 axis.
The vast majority (>99%) of cases are caused by a GH-secreting adenoma within the pituitary gland.
Rarely, acromegaly can be caused by ectopic tumors that secrete either GHRH (stimulating the pituitary) or GH itself.

Now that we have a firm grasp of the underlying hormonal and pathological processes, we are ready to explore their consequences. In the next lesson, we will describe the characteristic physical features that develop as a result of chronic GH and IGF-1 excess.